Li CY, Dai YX, Chang YT, et al. - Study of Taiwan National Health Insurance Research Database revealed that proton pump inhibitor (PPI) use might be related to an elevated risk of developing psoriasis or as an epiphenomenon.

• Patients with PPI use and an incidence of psoriasis (n = 5,756) were allocated to the case cohort and 1:1 matched to controls.

• A significant link was found between PPI use and psoriasis risk.

• Relative to PPI nonusers, confounder-adjusted odd ratios (95% confidence interval [CI]) were estimated to be 1.52 (1.31–1.76) and 1.54 (1.22–1.93) for patients with 120–365 cDDDs (cumulative defined daily doses) and >365 cDDDs, respectively.

• Lansoprazole use (OR, 1.25) was linked with subsequent psoriasis risk.